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Introduction
Neisseria meningitidis has become a leading cause of bacte-
rial meningitis in the United States after dramatic reductions
in the incidence of Streptococcus pneumoniae (1) and
Haemophilus influenzae type b (Hib) (2) infections have been
achieved as a result of using conjugate vaccines. CDC’s Advi-
sory Committee on Immunization Practices (ACIP) previously
recommended a tetravalent polysaccharide vaccine
(Menomune®-A,C,Y,W-135, manufactured by Sanofi Pasteur,
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Summary
In January 2005, a tetravalent meningococcal polysaccharide-protein conjugate vaccine ([MCV4] Menactra,™ manufac-
tured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) was licensed for use among persons aged 11–55 years. CDC’s Advisory
Committee on Immunization Practices (ACIP) recommends routine vaccination of young adolescents (defined in this report as
persons aged 11–12 years) with MCV4 at the preadolescent health-care visit (at age 11–12 years). Introducing a recommenda-
tion for MCV4 vaccination among young adolescents might strengthen the role of the preadolescent visit and have a positive effect
on vaccine coverage among adolescents. For those persons who have not previously received MCV4, ACIP recommends vaccina-
tion before high-school entry (at approximately age 15 years) as an effective strategy to reduce meningococcal disease incidence
among adolescents and young adults. By 2008, the goal will be routine vaccination with MCV4 of all adolescents beginning at
age 11 years. Routine vaccination with meningococcal vaccine also is recommended for college freshmen living in dormitories and
for other populations at increased risk (i.e., military recruits, travelers to areas in which meningococcal disease is hyperendemic or
epidemic, microbiologists who are routinely exposed to isolates of Neisseria meningitidis, patients with anatomic or functional
asplenia, and patients with terminal complement deficiency). Other adolescents, college students, and persons infected with
human immunodeficiency virus who wish to decrease their risk for meningococcal disease may elect to receive vaccine.
This report updates previous reports from ACIP concerning prevention and control of meningococcal disease. It also provides
updated recommendations regarding use of the tetravalent meningococcal polysaccharide vaccine (MPSV4) and on antimicrobial
chemoprophylaxis.
Inc., Swiftwater, Pennsylvania) for use among certain popula-
tions at increased risk, including travelers to countries with
epidemic or hyperendemic meningococcal disease, persons
who have certain medical conditions (i.e., terminal comple-
ment component deficiencies and anatomic or functional
asplenia), and laboratory personnel who are routinely exposed
to N. meningitdis in solutions that might be aerosolized (3).
Use of this vaccine also was recommended for control of men-
ingococcal disease outbreaks (4). Recommendations permit-
ting use of MPSV4 among college freshmen have been
published previously (5).
The new tetravalent A, C, Y, W-135 conjugate vaccine
(Menactra™, manufactured by Sanofi Pasteur, Inc.) licensed
for persons aged 11–55 years should become a key addition
to existing meningococcal disease prevention measures. This
report provides ACIP’s recommendations on prevention and
control of meningococcal disease, including recommendations
on use of the new tetravalent conjugate vaccine (MCV4) as
well as updated recommendations on use of the polysaccharide
vaccine (MPSV4) and on antimicrobial chemoprophylaxis.
The material in this report originated in the National Center for
Infectious Diseases, Ann Schuchat, MD, Acting Director, Division of
Bacterial and Mycotic Diseases, Judith Aguilar, Acting Director; and
the National Immunization Program, Stephen Cochi, MD, Acting
Director, Epidemiology and Surveillance Division, Gina Mootrey, DO,
Acting Director, and Immunization Services Division, Lance
Rodewald, MD, Director.
Corresponding preparer: Oleg Bilukha, MD, PhD, National Center
for Infectious Diseases, CDC, 1600 Clifton Road NE, MS C-09,
Atlanta, GA, 30333. Telephone: 404-639-1367; Fax: 404-639-3059;
e-mail: OBB0@cdc.gov.




Each year, an estimated 1,400–2,800 cases of meningococ-
cal disease occur in the United States, a rate of 0.5–1.1/100,000
population (CDC, unpublished data, 2004). N. meningitidis
colonizes mucosal surfaces of nasopharynx and is transmitted
through direct contact with large droplet respiratory secre-
tions from the patients or asymptomatic carriers. Humans are
the only host. Despite the continued sensitivity of meningo-
coccus to multiple widely available antibiotics, including peni-
cillin (6,7), the case-fatality ratio for meningococcal disease is
10%–14% (CDC, unpublished data, 2004). Meningococcal
disease also causes substantial morbidity; 11%–19% of survi-
vors have sequelae (e.g., neurologic disability, limb loss, and
hearing loss) (8,9). During 1991–2002, the highest rate of
meningococcal disease (9.2/100,000) occurred among infants
aged <1 year; the rate for persons aged 11–19 years (1.2/
100,000) also was higher than that for the general population
(Figure 1). Although rates of disease are highest among chil-
dren aged <2 years, 62% of meningococcal disease in the
United States occurs among persons aged >11 years (CDC,
unpublished data, 2004).
In the United States, >98% of cases of meningococcal dis-
ease are sporadic; however, since 1991, the frequency of local-
ized outbreaks has increased (10,11). The proportion of
meningococcal cases caused by serogroup Y increased from
2% during 1989–1991 (12) to 37% during 1997–2002
(CDC, unpublished data, 2004). Serogroups B, C, and Y are
the major causes of meningococcal disease in the United States,
each being responsible for approximately one third of cases.
The proportion of cases caused by each serogroup varies by
age group. Among infants aged <1 year, >50% of cases are
caused by serogroup B, for which no vaccine is licensed or
available in the United States (13,14). Of all cases of menin-
gococcal disease among persons aged >11 years, 75% are caused
by serogroups (C, Y, or W-135), which are included in vac-
cines available in the United States (CDC, unpublished data,
2004).
Persons who have deficiencies in the terminal common
complement pathway (C3, C5–9) (15,16) and those with
anatomic or functional asplenia (17) are at increased risk for
acquiring meningococcal disease. Antecedent viral infection,
household crowding, chronic underlying illness, and both
active and passive smoking also are associated with increased
risk for meningococcal disease (18–25). During outbreaks,
bar or nightclub patronage and alcohol use also have been
associated with higher risk for meningococcal disease (26–28).
In the United States, blacks and persons of low socioeco-
nomic status (SES) have been consistently at higher risk for
meningococcal disease (12,13). However, race and low SES
are likely risk markers rather than risk factors for this disease.
A multistate case-control study in which controls were matched
to case-patients by age group indicated that in a multivariable
analysis (controlling for sex and education), active and pas-
sive smoking, recent respiratory illness, corticosteroid use, new
residence, new school, Medicaid insurance, and household
crowding all were associated with increased risk for meningo-
coccal disease, whereas income and race were not (18). Addi-
tional research is needed to identify groups at risk that might
benefit from prevention efforts.
Meningococcal Disease and College
Students
Multiple studies have been conducted in the United States
(29–31) and the United Kingdom (32,33) concerning the risk
for meningococcal disease among college students. The risk
for meningococcal disease among U.S. college students was
higher for those who resided in dormitories than for those
residing in other types of accommodations. Overall incidence
among college students usually is similar to or somewhat lower
than that observed among persons in the general population
of similar age.
The earliest of these studies (conducted during the 1990–
91 and 1991–92 academic years) had a poor response rate
(38%) and indicated a low overall incidence of meningococ-
cal disease among U.S. college students (1.0/100,000 popu-
lation/year) (31). Cases of meningococcal disease occurred
9–23 times more frequently among students living in dormi-
tories than among those living in other types of accommoda-
FIGURE 1. Rate* of meningococcal disease, by age — United
States, 1991–2002
Source: Active Bacterial Core surveillance data.
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tions. A retrospective cohort study conducted in Maryland
during 1992–1997 (30) indicated that the overall incidence
of meningococcal disease among college students was similar
to that among the U.S. population of persons the same age
(1.7/100,000 and 1.4/100,000, respectively); however, rates
of disease among students living in dormitories were higher
than rates among students living off campus (3.2/100,000
and 1.0/100,000, respectively; p = 0.05).
U.S. surveillance data from the 1998–99 school year (29)
indicated that the overall rate of meningococcal disease among
undergraduate college students was lower than the rate among
persons aged 18–23 years who were not enrolled in college
(0.7 and 1.4/100,000, respectively) (Table 1). Rates were some-
what higher among freshmen (1.9/100,000). Among the
approximately 600,000 freshmen living in dormitories, rates
were higher (5.1/100,000) than among any age group in the
population other than children aged <2 years but lower than
the threshold (10/100,000) recommended for initiating men-
ingococcal vaccination campaigns (4). In a case-control study
involving 50 cases detected among college students (29), mul-
tivariate analysis indicated that freshmen living in dormito-
ries were at higher risk for meningococcal disease than other
students (matched odds ratio [OR]: 3.6; 95% confidence
interval [CI] = 1.6–8.5).
In the United Kingdom, rates of meningococcal disease were
higher among university students than among nonstudents
of similar age (32). Regression analysis indicated that the main
risk factor was catered hall accommodations (the U.K. equiva-
lent of U.S. dormitories). A recent study conducted in the
United Kingdom demonstrated a rapid increase in carriage
rates of meningococci among university students in the first
week of the fall semester, although rates of disease peaked later
in the academic year (33). The increased rate of disease among
university students has prompted the United Kingdom to ini-
tiate routine vaccination of incoming university students with
a bivalent A/C polysaccharide vaccine as part of a new vacci-
nation program (34).
In 2000, ACIP and the Committee on Infectious Diseases
of the American Academy of Pediatrics (AAP) concluded that
college students, especially those living in dormitories, are at
moderately increased risk for meningococcal disease compared
with other persons their age (5). ACIP and AAP recommended
that 1) college students and their parents be informed by
health-care providers of the risks of meningococcal disease and
of the potential benefits of vaccination with MPSV4; 2) col-
lege and university health services facilitate implementation
of educational programs about meningococcal disease and the
availability of vaccination services; and 3) MPSV4 be made
available to those persons requesting vaccination. As of
November 2004, a total of 31 states had adopted legislation
requiring colleges to provide information on risks of menin-
gococcal disease either to matriculating students or to stu-
dents residing on campus, and 10 states had mandated
vaccination for certain students, unless a vaccination waiver is
provided (Figure 2) (35).
In 2004, the American College Health Association con-
ducted an Internet-based survey of college policies and prac-
tices related to meningococcal vaccination (36). Of the 72
(10%) contacted colleges and universities that responded, 60%
reported having a written policy on meningococcal vaccina-
tion, and 80% reported conducting some type of outreach
awareness program among college students or their parents.
Median vaccination rates reported for the 2002–03 and
2003–04 academic years were 20% and 35%, respectively;
FIGURE 2. States with legislation requiring colleges to
provide information on risks of meningococcal disease
(Group 1)  and states with mandated vaccination for certain
students  (Group 2)
Group 1 status
Groups 1 and  2 status
TABLE 1. Number of cases and rates of meningococcal
disease — United States, September 1998–August 1999*
No. of cases Population Rate*
All persons aged 18–23 years 304 22,070,535† 1.4
Nonstudents aged 18–23 years 211 14,579,322†§ 1.4
All college and university students 96 14,897,268§ 0.6
Undergraduates 93 12,771,228§ 0.7
Freshmen¶ 44 2,285,001§ 1.9
Dormitory residents 48 2,085,618§** 2.3
Freshmen§ living in dormitories 30 591,587§** 5.1
Source: Bruce MG, Rosenstein NE, Capparelle JM, Shutt KA, Perkins BA,
Collins M. Risk factors for meningococcal disease in college students. JAMA
2001;286:688–93.
* Per 100,000 population.
† 1998 census data.
§ Source: National Center for Education Statistics, U.S. Department of
Education, 1996–1997.
¶ Students enrolled for the first time in any postsecondary educational
institution.
** Source: National College Health Risk Behavior Survey (NCHRBS) —
United States, 1995.
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67% reported an increase in vaccination rates during the pre-
vious 3 years. On the basis of the number of vaccine doses
sold, during the 2004–05 academic year, approximately 1.1
million college students received MPSV4 before arrival on
campus, and an estimated 50,000–100,000 students received





Since the early 1990s, outbreaks of meningococcal disease
have occurred with increasing frequency in the United States.
During July 1994–June 2002, a total of 76 outbreaks were
identified (annual median: 10; range: 4–16) (11), including
48 (63%) outbreaks caused by serogroup C, 19 (25%) by
serogroup B, and nine (12%) by serogroup Y. These outbreaks
occurred in 32 states and involved 247 patients (accounting
for <2% of total cases of meningococcal disease in the United
States during this period). Of the 76 outbreaks, 26 (34%)
were community-based and accounted for 53% of all outbreak-
related cases. Of the 50 (65%) outbreaks that were
organization-based, 13 (26%) occurred in colleges; 19 (38%)
in primary and secondary schools; and nine (18%) in nursing
homes. Vaccination campaigns (using an average of 2,500 doses
of MPSV4 per outbreak) were conducted in 34 outbreaks (30
of which were caused by serogroup C and four by serogroup
Y) (11).
The decision to implement a mass vaccination campaign to
prevent meningococcal disease depends on whether the
occurrence of more than one case represents an outbreak or
an unusual clustering of endemic disease. Because the num-
ber of cases in outbreaks is usually not substantial, this deter-
mination often requires evaluation and analysis of the patterns
of disease occurrence. Mass vaccination campaigns are expen-
sive, require a massive public health effort, and can create
unwarranted concern among the public. Detailed informa-
tion on evaluation and management of suspected outbreaks
has been published previously (4) and is presented in this
report.
Case Definitions
The following case definitions are used in this report:
• Confirmed case. A confirmed case of meningococcal dis-
ease is one that is defined by isolation of N. meningitdis
from a normally sterile site (e.g., blood or cerebrospinal
fluid) from a person with clinically compatible illness.
• Probable case. A probable case of meningococcal disease
is one that is defined by detection of polysaccharide anti-
gen in cerebrospinal fluid (e.g., by latex agglutination,
polymerase chain reaction, or immunohistochemistry) or
the presence of clinical purpura fulminans in the absence
of diagnostic culture from a person with clinically
compatible illness (37).
• Primary case. A primary case of meningococcal disease
is one that occurs in the absence of previous known close
contact with another patient.
• Secondary case. A secondary case of meningococcal dis-
ease is one that occurs among close contacts of a primary
patient >24 hours after onset of illness in the primary
patient.
• Co-primary cases. Co-primary cases are two or more cases
that occur among a group of close contacts with onset of
illness separated by <24 hours.
• Close contacts. Close contacts of a patient who has
meningococcal disease include 1) household members;
2) child-care center contacts; and 3) persons directly
exposed to the patient’s oral secretions (e.g., by kissing,
mouth-to-mouth resuscitation, endotracheal intubation,
or endotracheal tube management).
Organization- and Community-
Based Outbreaks
An outbreak usually is classified as organization-based if it
involves the occurrence of three or more confirmed or prob-
able cases of meningococcal disease of the same serogroup in
<3 months among persons who have a common affiliation
but no close contact with each other, resulting in primary dis-
ease attack rate of >10 cases/100,000 persons. Calculation of
attack rates for organization-based outbreaks is most useful
for large organizations (e.g., universities). However, in the
majority of organization-based outbreaks with three or even
two cases of disease, the rate will be >10 cases/100,000 popu-
lation. In such situations, public health officials also might
consider vaccination after only two primary cases are identified.
An outbreak is classified as community-based if it involves
the occurrence of three or more confirmed or probable cases
of meningococcal disease in <3 months among persons resid-
ing in the same area who are not close contacts of each other
and who do not share a common affiliation, with a primary
disease attack rate of >10 cases/100,000 persons. Distinguish-
ing whether an outbreak should be classified as organization-
or community-based is complicated by the fact that, in cer-
tain instances, these types of outbreaks occur simultaneously.
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Population at Risk
In addition to close contacts, persons considered to be at
increased risk for meningococcal disease compared with
historical rates of disease in the same population in the gen-
eral U.S. population are classified as being at risk. The popu-
lation at risk is used as the denominator in calculations of the
disease attack rate. The population at risk is usually defined
on the basis of organizational affiliation or community of resi-
dence. In organization-based outbreaks, cases are linked by a
common affiliation other than a shared, geographically delin-
eated community; the population at risk is thus usually the
group of persons who best represent that affiliation. For
example, if the only association between patients is attending
the same school or university, the population at risk is all per-
sons attending the school or university. In community-based
outbreaks, patients have no common affiliation other than a
shared, geographically defined community. The population
at risk can be defined as the smallest geographically contigu-
ous population that includes all (or nearly all) patients. This
population is usually a neighborhood, town, city, or county,
whose size is obtained from census data.
Attack Rate and Decision To Vaccinate
For a primary attack rate to be calculated, all confirmed
cases of the same serogroup should be summed; secondary
cases should be excluded and each set of co-primary cases
counted as one case. Because attack rates are calculated both
to characterize the risk for disease among the general popula-
tion and to determine whether overall rates have increased,
related cases (secondary and co-primary) should not be
included. From an epidemiologic perspective, secondary and
co-primary cases can be considered as representing single epi-
sodes of disease with direct spread to one or more close
contact(s), which is consistent with endemic disease.
If three or more cases have occurred in either an organiza-
tion- or a community-based outbreak during <3 months (start-
ing at the time of the first confirmed or probable case), a
primary attack rate should be calculated. Because of the lim-
ited number of cases typically involved and the seasonal pat-
terns of meningococcal disease (more cases occur during fall
than other times of the year), rate calculations should not be
annualized. The following formula is used to calculate attack
rates:
Attack rate per 100,000 = [(number of primary confirmed
or probable cases during a 3-month period) / (number of popu-
lation at risk)] x 100,000
Vaccination of the population at risk should be considered
if the attack rate is >10 cases/100,000 persons. The actual
attack rate at which the decision to vaccinate is made varies.
Public health personnel should consider the following factors:
1) completeness of case reporting and number of possible cases
of meningococcal disease for which bacteriologic confirma-
tion or serogroup data are not available; 2) occurrence of
additional cases of meningococcal disease after recognition of
a suspected outbreak (e.g., if the outbreak occurred 2 months
previously and if no additional cases have occurred, in which
case vaccination might be unlikely to prevent additional cases
of meningococcal disease); and 3) logistic and financial con-
siderations. Because available vaccines are not effective against
N. meningitdis serogroup B, vaccination should not be
considered during serogroup B outbreaks.
Vaccination Group
Those persons designated to be administered vaccine dur-
ing a vaccination campaign comprise a vaccination group. The
vaccination group usually includes either the whole or a sub-
set of the population of risk. Because meningococcal disease
outbreak cases occur predominantly among persons aged
<30 years (10,11), and available vaccines are not recommended
among children aged <2 years, the vaccination group usually
is that portion of the population at risk aged 2–29 years.
In the majority of organization-based outbreaks, the vacci-
nation group includes the whole population at risk, provided
that all persons are aged >2 years. If a substantial proportion
of patients are aged <2 years and thus are not eligible to
receive vaccine, patients aged <2 years should be excluded,
and, if at least three patients remain, the attack rate should
be recalculated. If the recalculated attack rate remains >10
cases/100,000 persons, vaccination should be considered for
part or all of the population at risk aged >2 years. In certain
organization-based outbreaks, a vaccination group larger than
the population at risk might be designated. For example, in a
high school in which all outbreak-associated cases occurred
among students, authorities might decide to offer vaccine to
staff. In community-based outbreaks, the vaccination group
usually can be defined as a subset of the population at risk
(e.g., persons aged 2–29 years). If a substantial proportion of
patients are aged <2 years, these patients might be excluded
from calculation of an attack rate. In rare situations (e.g., in a
town with a limited population) in which multiple cases have
occurred among adults aged >29 years, the entire population
aged >2 years might be considered for vaccination. For more
substantial populations, this decision would be costly in terms
of finances and human resources, and restricting the vaccina-
tion group to the persons in age groups with the highest
attack rates might be more appropriate. Age-specific attack
rates can be calculated by using the formula previously pro-
vided and by restricting the numerator and denominator to
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persons within specific age groups (e.g., persons aged 2–29
years).
Genotyping of N. meningitdis Isolates
Genotyping of N. meningitdis isolates by using such meth-
ods as pulsed-field gel electrophoresis or ribotyping might pro-
vide useful information for determining whether a group of
cases represents an outbreak (38). Outbreaks of meningococ-
cal disease usually are caused by closely related strains.
Genotyping data can allow identification of an outbreak strain
and help to better define the extent of the outbreak. If strains
from a group of patients are unrelated by genotyping, the group
of cases most likely does not represent an outbreak. Because
molecular subtyping testing might not be readily available or
accessible, initiation of outbreak-control efforts should not
be delayed until genotyping results are available.
Other Control Measures
Mass chemoprophylaxis (i.e., administration of antibiotics
to substantial populations) is not recommended to control
large outbreaks of disease. Disadvantages of mass chemopro-
phylaxis include cost of the drug and administration, diffi-
culty of ensuring simultaneous administration of drugs to
substantial populations, drug side effects, and emergence of
resistant organisms. In addition, multiple sources and pro-
longed risk for exposure make this approach impractical and
unlikely to succeed. In the majority of outbreak settings, these
disadvantages outweigh the possible benefit in disease pre-
vention. However, in outbreaks involving limited populations
(e.g., an outbreak in a single school), administration of chemo-
prophylaxis might be considered (39), especially in serogroup
B outbreaks, for which available vaccines are not effective (40).
When making a decision about initiating mass chemopro-
phylaxis in these settings, public health officials should con-
sider not only the potential for prevention of new cases but
also the logistics, cost, and potential for developing antimi-
crobial resistance (39,41). If mass chemoprophylaxis is
undertaken, it should be administered to all targeted persons
at the same time. In the United States, measures that have not
been recommended for control of meningococcal disease out-
breaks include restricting travel to areas with an outbreak, clos-
ing schools or universities, or canceling sporting or social
events.
Educating communities, physicians, and other health-care
workers about meningococcal disease to promote an early case
recognition and early care-seeking behaviors is an important
part of managing suspected meningococcal disease outbreaks.
Education efforts should be initiated as soon as an outbreak
of meningococcal disease is suspected (4). Information about






MPSV4 is a tetravalent meningococcal polysaccharide
vaccine (Menomune-A,C,Y,W-135, manufactured by Sanofi
Pasteur, Inc., Swiftwater, Pennsylvania) available in the United
States (42). Each dose consists of the four (A, C, Y, W-135)
purified bacterial capsular polysaccharides (50 µg each).
MPSV4 (Menomune) is available in single-dose (0.5-mL) and
10-dose (5-mL) vials; 50-dose vials are no longer available.
Vaccine Immunogenicity and Efficacy
The immunogenicity and clinical efficacy of the serogroups
A and C meningococcal vaccines have been well established.
The serogroup A polysaccharide induces antibody response
among certain children as young as age 3 months, although a
response comparable with that occurring in adults is not
achieved until age 4–5 years; the serogroup C component is
poorly immunogenic among recipients aged <18–24 months
(43,44). The serogroups A and C vaccines have demonstrated
estimated clinical efficacies of >85% among school-aged chil-
dren and adults and are useful in controlling outbreaks
(45–49). Serogroups Y and W-135 polysaccharides are safe
and immunogenic among adults and children aged >2 years
(50–52); although clinical protection has not been docu-
mented, vaccination with these polysaccharides induces pro-
duction of bactericidal antibodies. The antibody responses to
each of the four polysaccharides in the tetravalent vaccine are
serogroup specific and independent.
Persons whose spleens have been removed because of trauma
or nonlymphoid tumors and persons who have inherited
complement deficiencies have acceptable antibody responses
to polysaccharide meningococcal vaccine (53–55). A 2003
study indicated that tetravalent polysaccharide vaccine sub-
stantially reduced the incidence of invasive meningococcal
disease among patients with terminal complement deficiency
compared with similar patients who were unvaccinated (16).
Reduced clinical efficacy has not been demonstrated among
persons who have received multiple doses of vaccine. How-
ever, recent serologic studies have reported that multiple doses
of serogroup A and C polysaccharide vaccine might cause
immunologic hyporesponsiveness (i.e., a reduced antibody
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response after subsequent challenge with the same polysac-
charide antigen) to group A (56,57) and C (58,59) polysac-
charide. The clinical relevance of such hyporesponsiveness is
unclear.
Duration of Protection
Among infants and children aged <5 years, measurable lev-
els of antibodies against group A and C polysaccharides
decreased substantially during the first 3 years after a single
dose of vaccine; among healthy adults, antibody levels also
decreased, but antibodies were still detectable <10 years after
vaccine administration (43,60–63). Similarly, although
vaccine-induced clinical protection likely persists among
school-aged children and adults for >3 years, the efficacy of
the group A vaccine among children aged <5 years might
decrease markedly within this period. In one study, efficacy
among children aged <4 years at the time of vaccination
declined from >90% to <10% within 3 years after vaccina-
tion; efficacy was 67% among children who were aged >4 years
when vaccinated (64).
Precautions and Contraindications
Meningococcal polysaccharide vaccines have been used
extensively in mass vaccination programs as well as in the mili-
tary and among international travelers. Adverse reactions to
polysaccharide meningococcal vaccines are usually mild; the
most frequent reaction is pain and redness at the injection
site, lasting for 1–2 days. Estimates of the incidence of such
local reactions have varied (range: 4%–56%) (65,66). In cer-
tain studies, transient fever occurred among <5% of persons
vaccinated, more commonly among infants (44,67).
Severe reactions to polysaccharide meningococcal vaccine
are uncommon (44,52,65–71). The majority of studies
report the rate of systemic allergic reactions (e.g., urticaria,
wheezing, and rash) as 0–0.1/100,000 vaccine doses (44,71).
Anaphylaxis has been documented among <0.1/100,000 vac-
cine recipients (42,70). Neurologic reactions (e.g., seizures,





Bacterial polysaccharides, including those comprising the
capsule of N. meningitdis, are T-cell–independent antigens.
T-cell–independent antigens do not elicit a memory response;
they stimulate mature B-lymphocytes but not T-lymphocytes,
thus inducing a response that is neither long-lasting nor char-
acterized by an anamnestic response after subsequent chal-
lenge with the same polysaccharide antigen (72). Thus,
meningococcal polysaccharide vaccines have inherent limita-
tions. The serogroup C polysaccharide is poorly immunogenic
among children aged <2 years (73–75). The A polysaccharide
induces antibody response in infants, but vaccine efficacy
declines rapidly (64). Meningococcal polysaccharide vaccines
do not confer long-lasting immunity (61,64); they also do
not cause a sustainable reduction of nasopharyngeal carriage
of N. meningitdis (76,77) and therefore do not substantially
interrupt transmission to elicit herd immunity. Finally, mul-
tiple doses of serogroup A and C polysaccharide vaccine might
cause immunologic hyporesponsiveness to the group A (56,57)
and C (58,59) polysaccharide, although clinical implications
of this phenomenon are unknown.
Conjugation (i.e., covalent coupling) of polysaccharide to a
protein carrier that contains T-cell epitopes changes the
nature of immune response to polysaccharide from T-cell–
independent to T-cell–dependent, leading to a substantial pri-
mary response among infants and a strong anamnestic response
at re-exposure (78). Both conjugate Hib and conjugate
S. pneumoniae vaccines (introduced for mass infant immuni-
zation in the United States in 1990 and 2000, respectively)
have reduced incidence of disease caused by vaccine-
preventable serotypes (1,79). In addition, both vaccines
reduce asymptomatic carriage of respective bacteria (80–82),
thus protecting unvaccinated persons through a herd immu-
nity effect (1).
Meningococcal Serogroup C Conjugate
Vaccine in the United Kingdom
In November 1999, monovalent serogroup C conjugate
vaccines were introduced in the United Kingdom. The
national vaccination campaign introduced a routine 3-dose
infant vaccination series and implemented a mass catch-up
campaign during 1999–2000 targeting all persons aged
12 months–17 years (34). The three serogroup C conjugate
vaccines used in the United Kingdom are Meningtec™ (Wyeth
Lederle Vaccines and Pediatrics, Pearl River, New York);
Menjugate™ (Chiron Vaccines, Siena, Italy); and NeisVac™
(Baxter Hyland Immuno, Beltsville, Maryland). Two vaccines
(Meningtec and Menjugate) contain short-chain oligosaccha-
ride (O-acetylated) derived from serogroup C capsular polysac-
charide, conjugated to CRM197, a nontoxic mutant
diphtheria toxin. The third vaccine (NeisVac) contains
serogroup C polysaccharide (de-O-acetylated) conjugated to
tetanus toxoid (83,84). The serogroup C conjugate meningo-
coccal vaccines used in this campaign were licensed on the
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basis of data on safety and immunogenicity but without data
on clinical efficacy (85).
By 2001–2002, vaccine coverage in the United Kingdom
was estimated as 80% among infants, 84% among toddlers,
76% among preschoolers, and 86%–87% among
schoolchildren (86). Effectiveness of the vaccine within the
first year of vaccination ranged from 88% to 98% among dif-
ferent age groups (87–89). Insufficient data are available to
differentiate efficacy of the three meningococcal conjugate vac-
cines. Because the vaccine campaign was initiated only in 1999,
long-term data on duration of protection are not yet avail-
able. However, among infants who received 3 doses of vac-
cine at ages 2, 3, and 4 months, efficacy declined to -81%
(95% CI = -7,430–71) after only 1 year (88). Although the
number of cases remains low, likely in part as a result of vaccine-
induced herd immunity, this study raises questions about the
meningococcal vaccine schedule and the need for a booster
dose.
During 1999–2000, carriage rates of group C meningo-
cocci in the United Kingdom declined 66% (90). In addi-
tion, incidence of meningococcal serogroup C disease declined
67% among unvaccinated persons aged 1–17 years and 35%
among persons aged >25 years who were not targeted for vac-





MCV4 is a tetravalent meningococcal conjugate vaccine
(Menactra, manufactured by Sanofi Pasteur, Inc., Swiftwater,
Pennsylvania) that was licensed for use in the United States in
January 2005. A 0.5-mL single dose of vaccine contains 4 µg
each of capsular polysaccharide from serogroups A, C, Y, and
W-135 conjugated to 48 µg of diphtheria toxoid. MCV4 is
available only in single-dose vials.
Immunologic Correlates of Protection
Studies among U.S. military recruits conducted in the 1960s
indicated that the absence of naturally acquired bactericidal
antibodies, measured by a serum bactericidal antibody assay
(SBA) using an intrinsic human complement source, was
associated with susceptibility to meningococcal group C dis-
ease. SBA titers >4 using human serum as an exogenous
complement source (hSBA) are considered the standard cor-
relate of clinical protection against serogroup C meningococ-
cal disease (91).
Serogroup C conjugate meningococcal vaccines were
licensed in the United Kingdom on the basis of data on safety
and immunogenicity, without data on clinical efficacy (85).
The immunologic data supporting the use of conjugate
serogroup C vaccines were generated by serum bactericidal
assay by using baby rabbit complement (rSBA). The thresh-
old values were validated by comparing rSBA titers with those
obtained by using hSBA (85,92). For licensure in the United
Kingdom, rSBA titers of >128 were considered to predict pro-
tection; however, only 60% of rSBA titers in the range of 8–64
had hSBA titers of >4. For rSBA titers in this equivocal range,
a fourfold rise in titers pre- to postvaccination was also
proposed as a correlate of protection (92).
Further evaluation of these threshold values was performed
by using vaccine efficacy estimates from postlicensure surveil-
lance, which indicated that these threshold values provided a
conservative estimate of short-term clinical efficacy; rSBA
threshold of >128 underestimated efficacy, with rSBA cutoffs
of >4–>8 at 4 weeks after vaccination being most consistent
with observed clinical efficacy (93). On the basis of these effi-
cacy estimates, the proportion of responders in multiple clini-
cal trials of meningococcal C conjugate vaccines, and the group
C seroprevalence study conducted before introduction of group
C conjugate vaccines (94), rSBA titers of <8 have been pro-
posed to be predictive of susceptibility to invasive meningo-
coccal disease, and rSBA titers of >8 have been proposed to
correlate with short-term protection (95). Limited or no similar
data exist to link immune response with clinical efficacy for
serogroups A, Y, or W-135.
In 1981, MPSV4 (Menomune) was licensed in the United
States on the basis of data on safety and immunogenicity.
Immunogenicity of this vaccine was compared with that of
the vaccine then licensed for use in the United States, A/C
meningococcal polysaccharide vaccine, which had demon-
strated 97% efficacy against serogroup A and 90% efficacy
against serogroup C (96). The immunologic criterion used
for licensing was a fourfold or greater rise in SBA among 90%
of adults at 3–4 weeks after vaccination. As a result, in 2005,
MCV4 (Menactra) was licensed on the basis of findings indi-
cating that it was not inferior to MPSV4 in terms of immu-
nogenicity and safety (i.e., demonstrated noninferiority). A
primary criterion in determining immunogenic noninferiority
of the new vaccine was the percentage of vaccinees having a
fourfold or greater increase in bactericidal antibody for MCV4
compared with MPSV4.




A randomized controlled trial conducted among persons
aged 11–18 years compared immunogenicity of MCV4 with
that of MPSV4 at 28 days after vaccination. A similar
percentage of subjects achieved at least a fourfold rise in rSBA
titers in MCV4 and MPSV groups (Table 2). The percentage
of subjects with at least a fourfold rise in rSBA was highest for
serogroup W-135 (96.7% in MCV4 group and 95.3% in
MPSV4 group), and lowest for serogroup Y (81.8% and
80.1%, respectively). The percentage of subjects achieving an
rSBA geometric mean titer (GMT) of >128 was high (>98%
for all serogroups) in both MCV4 and MPSV4 groups (97,98).
Immunogenicity Among Persons
Aged 18–55 Years
Another randomized controlled trial conducted among per-
sons aged 18–55 years compared immunogenicity of MCV4
and that of MPSV4 at 28 days after vaccination. Although
the percentage of subjects achieving at least a fourfold increase
in rSBA titer for each serogroup was higher in the MPSV4
group than in the MCV4 group (Table 2), the criteria for
demonstrating immunologic noninferiority to MPSV4 were
still achieved. As was the case among persons aged 11–18 years,
this percentage was highest for serogroup W-135 (89.4% in
the MCV4 group and 94.4% in the MPSV4 group) and low-
est for serogroup Y (73.5% and 79.4%, respectively). The
percentage of subjects achieving an rSBA GMT of >128 was
high (>97% for all serogroups) in both MCV4 and MPSV4
groups (97,98).
Persistence of Antibodies After 3 Years and
Response to Revaccination
MCV4 was administered to 76 subjects previously vacci-
nated with MCV4, 77 subjects previously vaccinated with
MPSV4, and 88 age-matched vaccine-naïve subjects (97)
(Sanofi Pasteur, Inc., unpublished data, 2004). Immunologic
indices were measured before revaccination (day 0) and at days
8 and 28 after revaccination (Table 3).
Subjects initially vaccinated with MCV4 had higher rSBA
GMT at day 0 than those vaccinated with MPSV4 (Table 3);
this difference was statistically significant for serogroups A
(p<0.001) and W-135 (p<0.001). In addition, a higher per-
centage of those initially vaccinated with MCV4 had rSBA
titers of >128 than those initially vaccinated with MPSV4
(Table 3). Vaccine-naïve subjects had lower rSBA on day 0
than subjects previously vaccinated with either MCV4 or
MPSV4.
Response to revaccination with MCV4 was assessed by
administering MCV4 to subjects previously vaccinated with
MPSV4 or MCV4 and to vaccine-naïve control subjects. All
subjects in all three groups achieved rSBA titers of >128 at
both 8 and 28 days after receiving MCV4 (Table 3). Subjects
initially primed with MCV4 achieved higher rSBA GMTs than
naïve control subjects for all serogroups except A. In contrast,
rSBA GMTs of those primed with MPSV4 were lower than
those of vaccine-naïve control subjects on both days 8 and 28
for all serogroups (Table 3).
TABLE 2. Percentage of subjects achieving a fourfold rise or greater in serum bactericidal activity by using baby rabbit
complement (rSBA), rSBA geometric mean titer (GMT) of >128, and rSBA GMT, 28 days after vaccination with meningococcal
conjugate vaccine (MCV4) and meningococcal polysaccharide vaccine (MPSV4)
Fourfold or greater increase in rSBA titer rSBA GMT rSBA GMT >128
MCV4 MPSV4 MCV4 MPSV4 MCV4 MPSV4
Age group, serogroup % (95% CI*) % (95% CI) GMT GMT % %
Persons aged 11–18 yrs†
A 92.7 (89.8–95.0) 92.4 (89.5–94.8) 5,483 3,246 99.8 100.0
C 91.7 (88.7–94.2) 88.7 (85.2–91.5) 1,924 1,639 98.8 98.4
Y 81.8 (77.8–85.4) 80.1 (76.0–83.8) 1,322 1,228 99.5 99.3
W-135 96.7 (94.5–98.2) 95.3 (92.8–97.1) 1,407 1,545 98.6 98.8
Persons aged 18–55 yrs§
A 80.5 (78.2–82.6) 84.6 (82.3–86.7) 3,897 4,114 99.8 99.9
C 88.5 (86.6–90.2) 89.7 (87.8–91.4) 3,231 3,469 98.8 98.5
Y 73.5 (71.0–75.9) 79.4 (76.9–81.8) 1,750 2,449 97.0 98.5
W-135 89.4 (87.6–91.0) 94.4 (92.8–95.6) 1,271 1,871 97.1 98.5
Sources: Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, September 22, 2004: briefing information. Rockville,
MD: US Department of Health and Human Services, Food and Drug Administration; 2004. Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/
2004-4072b1.htm; Food and Drug Administration. Product approval information—licensing action. Rockville, MD: US Department of Health and Human
Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2005. Available at http://www.fda.gov/cber/products/
mpdtave011405.htm.
* Confidence interval.
†N = 423 in MCV4 group; 423 in MPSV4 group.
§N = 1,280 in MCV4 group; 1,098 in MPSV4 group.
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Concomitant Administration of MCV
and Other Vaccines
The concomitant administration of MCV4 and tetanus and
diphtheria toxoids adsorbed for adult use (Td, manufactured
by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) was evalu-
ated in a double-blind, controlled trial of participants aged
11–17 years. One group received Td and MCV4 concomi-
tantly at separate injection sites, followed by a saline placebo
28 days later; the other group received Td and a saline pla-
cebo at separate injection sites, followed 28 days later by
MCV4. Concomitant administration of Td and MCV4 did
not adversely affect immune response to either vaccine (97,98).
When MCV4 and Td were administered concomitantly,
antibody response to diphtheria antigen 28 days after vacci-
nation was greater (diphtheria GMT 120.9 IU/mL) than when
Td and MCV4 were administered sequentially, Td first (diph-
theria GMT 8.4 IU/mL 28 days after Td dose) followed by
MCV4 28 days after Td (diphtheria GMT 16.9 IU/mL 28
days after MCV4 dose) (97). The prelicensure data demon-
strated comparable overall safety profiles among adolescents
who received simultaneous and sequential vaccination (Td
followed by MCV4 28 days later). The immunological and
safety profiles among adolescents receiving MCV4 followed
by Td on a later date were not evaluated during prelicensure
trials (see “Safety of Concomitant Administration of MCV4
and Other Vaccines”).
Among adults aged 18–55 years, a randomized controlled
trial assessed immunogenicity of MCV4 and typhoid
vaccine 1) when MCV4 and typhoid vaccine were adminis-
tered concomitantly and 2) when typhoid vaccine was
administered concomitantly with placebo and MCV4 was ad-
ministered 28 days later. Concomitant administration did not
adversely affect immune response to either typhoid vaccine or
MCV4 (97,98).
Safety
Systemic and Local Adverse Reactions
Among persons aged 11–18 years, safety of MCV4 and
MPSV4 was assessed in two randomized controlled trials
(97,98). The percentage of subjects reporting systemic adverse
events was similar for persons who received either vaccine. In
one study, approximately half of the participants experienced
at least one systemic adverse reaction, and <5% experienced
at least one severe systemic reaction. Fever (i.e., temperature
>100ºF [>38ºC]) was reported by 5.1%  of those who
received MCV4 and by 3.0% of those who received MPSV4
(Table 4).
Among persons aged 18–55 years, the safety of MCV4 and
of MPSV4 also were compared in two randomized controlled
trials. The percentage of subjects reporting systemic adverse
events was similar for persons who received either vaccine. In
one study, 62% of participants experienced at least one
systemic adverse reaction, and <4% experienced severe sys-
temic reaction after receiving MCV4. Fever was reported by
1.5% of those who received MCV4 and by 0.5% of those
who received MPSV4 (Table 4).
Local adverse reactions were more common among those
persons aged 11–18 years who received MCV4 than among
those who received MPSV4 (Table 5); 13% of those who
TABLE 3. Geometric mean titer (GMT) of serum bactericidal activity by using baby rabbit complement (rSBA) and percentage
of subjects aged 14–21 years achieving rSBA GMT of >128 before (day 0) and at days 8 and 28 after revaccination with
meningococcal conjugate vaccine (MCV4) at 3 years after previous vaccination in three groups (primed with MCV4, primed
with meningococcal polysaccharide vaccine [MPSV4], and vaccine-naïve)
Day 0, rSBA GMT Day 8, rSBA GMT Day 28, rSBA GMT
Primed Primed Primed Primed Primed Primed
with with Vaccine- with with Vaccine- with with Vaccine-
Indicator, MCV4 MPSV4 naïve MCV4 MPSV4 naïve MCV4 MPSV4 naïve
serogroup (n = 76) (n = 77) (n = 88) (n = 76) (n = 77) (n = 88) (n = 76) (n = 77) (n = 88)
GMT
A 1,082 171 84 9,393 4,406 12,936 4,326 3,271 6,399
C 211 109 43 18,113 1,196 7,453 8,192 665 2,955
Y 592 380 211 12,808 2,896 7,053 5,846 2,327 4,366
W-135 447 120 22 9,566 1,921 5,657 4,612 1,578 2,955
% GMT >128
A 94.7 70.1 58.0 100.0 100.0 100.0 100.0 100.0 100.0
C 71.1 57.1 45.5 100.0 92.1 98.9 100.0 100.0 100.0
Y 96.1 83.1 74.7 100.0 97.4 100.0 100.0 100.0 100.0
W-135 83.1 67.5 28.4 100.0 100.0 100.0 100.0 100.0 100.0
Sources: Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, September 22, 2004: briefing information. Rockville,
MD: US Department of Health and Human Services, Food and Drug Administration; 2004. Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/
2004-4072b1.htm; Sanofi Pasteur, Inc., unpublished data, 2004.
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received MCV4 reported pain that limited movement in the
arm of injection, compared with 3% of those who received
MPSV4. These differences in frequency of local reactions are
related to the amount of diphtheria toxoid contained in each
vaccine (99). The frequency of local adverse reactions
reported after MCV4 was similar to that reported after Td
vaccine (97,98).
As with persons aged 11–18 years, local adverse reactions
among persons aged 18–55 years were reported more com-
monly by those who received MCV4 than by those who
received MPSV4 (Table 5). However, the frequency of local
adverse reactions reported by adults after MCV4 was similar
to that reported after typhoid vaccine (97,98).
Safety of Concomitant Administration of MCV4
and Other Vaccines
Among persons aged 11–17 years, frequency of reported
local adverse effects at MCV4 injection site in the group for
which MCV4 was administered concomitantly with Td was
similar to those in which MCV4 was administered 28 days
after Td. The percentage (58.6%) of subjects reporting at least
one systemic adverse reaction after concomitant administra-
tion of MCV4 and Td was similar to the percentage (54.1%)
of systemic reactions reported after Td was administered
concomitantly with a placebo. Among persons aged 18–55
years, the frequency of local and systemic adverse effects was
similar for those receiving concomitant administration of
MCV4 and typhoid vaccine and those who received MCV4
28 days after receiving typhoid vaccine (97,98).
Serious Adverse Events in All Safety Studies
A total of 5,453 subjects aged 11–55 years who received
MCV4 and 2,923 subjects in the same age group who
received MPSV4 completed follow-up 6 months after vacci-
nation. Serious adverse events reported within a 6-month
period after vaccination occurred at the same rate (1.3%) in
the MCV4 and MPSV4 groups. The events reported were
consistent with events expected among healthy adolescent and
adult populations (98).
TABLE 4. Percentage of subjects aged 11–18 years and those
aged 18–55 years reporting systemic adverse reactions* 0–7
days after vaccination with either meningococcal conjugate
vaccine (MCV4) or meningococcal polysaccharide vaccine
(MPSV4)
Persons aged Persons aged
11–18 yrs (%) 18–55 yrs (%)
MCV4 MPSV4 MCV4 MPSV4
Reaction n = 2,265 n = 970 n = 1,371 n =
1,159
Any systemic adverse reaction 55.1 48.7 61.9 60.3
Any severe† systemic adverse reaction 4.3 2.6 3.8 2.6
Fever 
>100.0ºF (>38.0ºC) 5.1§ 3.0§ 1.5§ 0.5§
>103.1ºF (>39.5ºC) 0.6 0.4
>104.0ºF (>40.0ºC) 0.3 0.1
Sources: Food and Drug Administration. Vaccines and Related Biological
Products Advisory Committee, September 22, 2004: briefing information.
Rockville, MD: US Department of Health and Human Services, Food and
Drug Administration; 2004. Available at http://www.fda.gov/ohrms/dockets/ac/
04/briefing/2004-4072b1.htm. Food and Drug Administration. Product approval
information—licensing action. Rockville, MD: US Department of Health and
Human Services, Food and Drug Administration, Center for Biologics
Evaluation and Research; 2005. Available at http://www.fda.gov/cber/products/
mpdtave011405.htm. Sanofi Pasteur, Inc., unpublished data, 2004.
* Including fever, headache, fatigue, malaise, chills, arthralgia, anorexia,
vomiting, diarrhea, seizures, or rash.
†Fever >103.1ºF (>39.5oC) for persons aged 11–18 years or >104.0ºF( >40.0oC)
for adults aged 18–55 years; headache, fatigue, malaise, chills, or arthralgia
requiring bed rest; anorexia or skipping three or more meals; three or more
episodes of vomiting; five or more episodes of diarrhea; or presence of rash
or seizures.
§Values in MCV4 and MPSV4 groups that are statistically different (p<0.05).
P values were calculated by using chi-square tests.
TABLE 5. Percentage of persons aged 11–18 years and
persons aged 18–55 years reporting local adverse reactions
0–7 days after vaccination with either meningococcal
conjugate vaccine (MCV4) or meningococcal polysaccharide
vaccine (MPSV4)
Persons aged Persons aged
11–18 yrs (%) 18–55 yrs (%)
MCV4 MPSV4 MCV4 MPSV4
Reaction (n = 2,265) (n = 970) (n = 1,371) (n = 1,159)
Redness
Any 10.9* 5.7* 14.4 16.0
1–2 inches 1.6* 0.4* 2.9 1.9
>2 inches 0.6* 0* 1.1* 0.1*
Swelling
Any 10.8* 3.68* 12.6* 7.6*
1–2 inches 1.9* 0.3* 2.3* 0.7*
>2 inches 0.5* 0* 0.9* 0*
Induration
Any 15.7* 5.2* 17.1* 11.0*
1–2 inches 2.5* 0.5* 3.4* 1.0*
>2 inches 0.3 0 0.7* 0*
Pain†
Any 59.2* 28.7* 53.9* 48.1*
Moderate 12.8* 2.6* 11.3* 3.3*
Severe 0.3 0 0.2 0.1
Sources: Food and Drug Administration. Vaccines and Related Biological
Products Advisory Committee, September 22, 2004: briefing information.
Rockville, MD: US Department of Health and Human Services, Food and
Drug Administration; 2004. Available at http://www.fda.gov/ohrms/dockets/
ac/04/briefing/2004-4072b1.htm. Food and Drug Administration. Product
approval information—licensing action. Rockville, MD: US Department of
Health and Human Services, Food and Drug Administration, Center for
Biologics Evaluation and Research; 2005. Available at http://www.fda.gov/
cber/products/mpdtave011405.htm. Sanofi Pasteur, Inc., unpublished data,
2004.
* Denotes values in MCV4 and MPSV4 groups that are statistically different
(p<0.05). P values were calculated for each category and severity by using
chi-square tests.
†Mild = symptoms present, but arm movement not affected; moderate =
usual arm movement limited; and severe = disabling.
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Cost-Effectiveness Analyses
Cost-Effectiveness Analysis of MPSV4
Vaccine Among College Students
From a societal perspective, the economic costs and ben-
efits of vaccinating 1) a cohort of 591,587 freshmen who live
in dormitories and 2) all freshmen enrolled in U.S. colleges,
regardless of housing status (N = 2.4 million) were evaluated,
on the basis of an assumption that the benefits of vaccination
would last 4 years (100). Best- and worst-case scenarios were
evaluated by varying the cost of vaccine and administration
(range: $54–$88), costs per hospitalization ($10,924–
$24,030), the value of premature death on the basis of life-
time productivity ($1.3 million–$4.8 million), the cost per
case of vaccine side effects ($7,000–$24,540/1 million doses),
and the average long-term cost of treating a case of sequelae of
disease ($1,298–$14,600). Vaccination coverage (60% and
100%, respectively) and vaccine efficacy (80% and 90%,
respectively) also were varied for evaluation purposes.
Vaccination of freshmen who live in dormitories would
result in the administration of approximately 354,950–
591,590 doses of vaccine each year, preventing 16–30 cases of
meningococcal disease and one to three deaths each year. The
cost per case prevented would be an estimated $617,000–$1.85
million, at a cost per death prevented of $6.8–$20.4 million
and a cost per life-year saved (LYS)* of $62,042–$489,185
(100). Vaccination of all freshmen would result in the admin-
istration of approximately 1,364,400–2,274,000 doses of vac-
cine each year, preventing 37–69 cases of meningococcal
disease and two to five deaths each year. The cost per case
prevented would be $1.4–$2.9 million, at a cost per death
prevented of $22–$48 million (100). These data are similar
to data derived from previous studies (101).
Cost-Effectiveness Analysis of MCV4
Vaccine Among Adolescents
Aged 11 Years
From a societal perspective, the economic costs and ben-
efits of vaccinating a cohort of approximately 4,238,670 U.S.
adolescents aged 11 years were evaluated, on the basis of an
assumption that the benefits of vaccination would last 22 years
(102). A multivariable (Monte Carlo) analysis was performed
in which multiple parameters were varied simultaneously over
specified probability distributions. These parameters included
disease incidence (46%–120% of the 10-year average), case-
fatality ratio (34%–131% of the 10-year average), rates of long-
term sequelae, acute meningococcal disease costs (i.e., inpatient
care, parents’ work loss, and public health response), lifetime
costs of meningococcal disease sequelae, and cost of vaccine
and administration (range: $64–$114). Vaccination coverage
(16%–95%) and vaccine efficacy (39%–99%) also were var-
ied for evaluation purposes.
Median program costs for vaccination of adolescents aged
11 years would be $227 million (5th–95th percentile: $158–
$406 million). If a 3% discount rate were used for costs and
benefits, during a 22-year period, vaccination among adoles-
cents would prevent 270 cases and 36 deaths (21 cases and
three deaths in the first year). The median cost would be
$633,000 (5th–95th percentile: $329,000–$1,299,000)/case
prevented; $5.0 million (5th–95th percentile: $2.4–$10.9
million)/death prevented; and $121,000 (5th–95th percen-
tile: $69,000–$249,000)/LYS saved (102).
Cost-Effectiveness Analysis of a Catch-
Up Vaccination Campaign with MCV4
The direct and indirect (herd immunity) benefits of a one-
time catch-up vaccination campaign with MCV4 of adoles-
cents aged 11–17 years followed by routine annual vaccination
of adolescents aged 11 years were analyzed (CDC, unpub-
lished data, 2005). For this purpose, a probabilistic model of
disease burden and economic impacts was built for a 10-year
period with and without an adolescent catch-up program. U.S.
age- and serogroup-specific surveillance data on incidence and
case fatality rates were used, as were hypothetical age-specific
reductions in attack rates among unvaccinated persons
obtained on the basis of U.K. data (86,103). Medical, work
loss, and public response costs were estimated with and with-
out a catch-up campaign, as were lifetime costs of meningo-
coccal disease sequelae. After disease and vaccination program
costs were projected, estimated costs per case averted, deaths
prevented, LYS, and quality-adjusted life years (QALY)† saved
were estimated.
With herd immunity effects equivalent to recent experience
in the United Kingdom, catch-up vaccination of adolescents
plus an added routine program would prevent 5,263 cases* The number of life-years saved as a result of a preventive intervention (i.e.,
the number of potential years of life expected if disease-specific events leading
to premature death not occur [healthy life expectancy]). The number of life-
years saved will be less or at the most equal to the number of potential years
lost pre-intervention. Because life expectancy is age-specific, life-years saved
is often calculated as the difference between the age-specific healthy life
expectancy and the age when a disease-specific event leading to premature
mortality could occur without the intervention.
† A measure based on individual preferences for states of health that assigns a
value of 1 to a year of perfect health and 0 to death. QALYs measure not
only years of life saved but also functioning and health preserved. QALYs are
highly relevant when disease-specific outcomes lead to both mortality (i.e.,
premature death) and substantial morbidity (i.e., temporal or permanent
disability). Thus, effectiveness outcomes are expressed as change in health status.
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during a 10-year period, a 32% reduction in the number of
cases. Excluding program costs, the catch-up program would
save $338 million in medical and public response costs and
$591 million in time off from work, long-term disability, and
premature death. At a hypothetical cost of $83 per vaccinee, a
catch-up vaccination program (including 9 years of routine
vaccination) would cost society approximately $3.6 billion
(45% of this sum in the first year). At a 3% discount rate, the
catch-up program would cost society $532,000/case averted,
$5.9 million/death prevented, $138,000/LYS, and $64,000/
QALY saved. A 20% reduction in herd immunity effects would
increase the cost per LYS by $21,000; a $30 decrease in the
cost of vaccination would decrease the cost per LYS by
$55,000. On the basis of the assumption that herd immunity
can be generated, targeting only those U.S. counties in which
the disease is highly endemic would decrease the cost per LYS
by two thirds.
Catch-up vaccination of adolescents can have a substantial
impact on disease burden and costs. However, these data dem-
onstrate that catch-up and routine vaccination programs with
MCV4 among adolescents are more costly per health out-
come than existing vaccination strategies for Hib and
S. pneumoniae (104,105). Compared with routine vaccina-
tion of children aged 11 years, catch-up vaccination could
cost up to 20% more/LYS.
Recommendations for Use
of Meningococcal Vaccines
Routine Vaccination of Adolescents
 ACIP recommends routine vaccination of young adoles-
cents (defined in this report as persons aged 11–12 years) with
MCV4 at the preadolescent health-care visit (i.e., a visit to a
health-care provider at age 11–12 years, at which time ACIP
and other professional organizations [e.g., AAP and the Ameri-
can Medical Association] recommend that persons aged 11–12
years receive appropriate vaccinations and other preventive
services [106–109]). Introducing a recommendation for
MCV4 vaccination among persons aged 11–12 years might
strengthen the role of the preadolescent health-care visit and
have a positive effect on vaccine coverage during adolescence.
For those adolescents who have not previously received MCV4,
ACIP recommends vaccination before high school entry (at
approximately age 15 years) as an effective strategy to reduce
meningococcal disease incidence among adolescents and young
adults. By 2008, the goal will be routine vaccination with
MCV4 of all adolescents beginning at age 11 years. Other
adolescents who wish to decrease their risk for meningococcal
disease may elect to receive vaccine.
Other Populations at Increased Risk
for Meningococcal Disease
Routine vaccination also is recommended for certain per-
sons who have increased risk for meningococcal disease
(Table 6). Use of MCV4 is preferred among persons aged
11–55 years; however, use of MPSV4 is recommended among
children aged 2–10 years and persons aged >55 years. If MCV4
is unavailable, MPSV4 is an acceptable alternative for persons
aged 11–55 years.
The following populations are at increased risk for menin-
gococcal disease:
• college freshmen living in dormitories (29,30);
• microbiologists who are routinely exposed to isolates of
N. meningitdis (110);
• military recruits (111);
• persons who travel to or reside in countries in which
N. meningitdis is hyperendemic or epidemic, particularly
if contact with the local population will be prolonged
(112);
• persons who have terminal complement component
deficiencies (15,16,113); and
• persons who have anatomic or functional asplenia (17).
Because of feasibility constraints in targeting freshmen in
dormitories, colleges can elect to target their vaccination cam-
paigns to all matriculating freshmen. The risk for meningo-
coccal disease among nonfreshmen college students is similar
to that for the general population of similar age (age 18–24
years) (29). However, the vaccines are safe and immunogenic
and therefore can be provided to nonfreshmen college
students who want to reduce their risk for meningococcal
disease.
For travelers, vaccination is especially recommended to those
visiting the parts of sub-Saharan Africa known as the “menin-
gitis belt” (112) during the dry season (December–June). Vac-
cination is required by the government of Saudi Arabia for all
travelers to Mecca during the annual Hajj. Advisories for trav-
elers to other countries will be issued when epidemics of men-
ingococcal disease caused by vaccine-preventable serogroups
are detected. Travelers’ health information is available from
CDC at 877-FYI-TRIP (toll-free) or at http://www.cdc.gov/
travel. Further information concerning geographic areas for
which vaccination is recommended can be obtained from in-
ternational health clinics for travelers and state health depart-
ments.
Patients with human immunodeficiency virus (HIV) are
likely at increased risk for meningococcal disease, although
not to the extent that they are at risk for invasive S. pneumoniae
infection (20,114). Although the efficacy of MCV4 among
HIV-infected patients is unknown, HIV-infected patients may
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elect vaccination. For persons aged 11–55 years who have been
previously vaccinated with MPSV4, revaccination with MCV4
is not indicated unless vaccination occurred 3–5 years previ-
ously and the person still remains at increased risk for menin-
gococcal disease (see Revaccination).
Adults Aged 20–55 Years
MCV4 is licensed for use among adults aged 20–55 years.
It is safe, immunogenic (97,98,115,116), and likely to pro-
vide relatively long-lasting protection against meningococcal
disease caused by serogroups A, C, Y, and W-135. The rates
of meningococcal disease are low in this age group, and vacci-
nation will decrease but not eliminate risk. Therefore, routine
vaccination is not recommended; however, persons who wish
to decrease their risk for meningococcal disease may elect to
be vaccinated.
Children Aged <11 Years and Adults
Aged >55 Years
MCV 4 is not licensed for use among children aged <11 years
or adults aged >55 years. Routine vaccination with MPSV4 is
not recommended for children aged <2 years because it is rela-
tively ineffective and offers a short duration of protection.
Routine vaccination with MPSV4 is not recommended for
children aged 2–10 years and adults aged >55 years who are
not identified as being at increased risk for meningococcal
disease.
Outbreaks of Meningococcal Disease
Both MPSV4 (4) and MCV4 are recommended for use in
control of meningococcal outbreaks caused by vaccine-
preventable serogroups (A, C, W-135, and Y) of N. meningitdis.
An outbreak is defined by the occurrence of at least three§
confirmed or probable primary¶ cases of serogroup C
meningococcal disease in <3 months, with a resulting pri-
mary attack rate of >10 cases/100,000 population. For calcu-
lation of this threshold, population-based rates are used rather
than age-specific attack rates. These recommendations are
based on experience with serogroup C meningococcal out-
breaks, but these principles might be applicable to outbreaks
caused by the other vaccine-preventable meningococcal
serogroups, including Y, W-135, and A. Both MCV4 and
MPSV4 can be used for outbreak control, although use of
TABLE 6. Recommendations for the use of meningococcal vaccines among persons not vaccinated previously
Age group (yrs)
Population group <2 2–10 11–19 20–55 >55
General population Not recommended Not recommended A single dose of MCV4* is Not recommended Not recommended
recommended at age
11–12 years (at preadolescent
assessment visit) or at high
school entry (at approximately
age 15 years)
Groups at increased risk Not usually A single dose A single dose of MCV4 is A single dose of A single dose
College freshmen living in dormitories recommended†  of MPSV4 preferred (MPSV4 is MCV4 is preferred of MPSV4
Certain travelers§  an acceptable alternative) (MPSV4 is an
Certain microbiologists¶ acceptable
Certain populations experiencing alternative)
outbreaks of meningococcal disease**
Military recruits
Persons with increased susceptibility††
* Meningococcal conjugate vaccine.
† Meningococcal polysaccharide vaccine (MPSV4) (2 doses, 3 months apart) can be considered for children aged 3–18 months to elicit short-term protection
against serogroup A disease (a single dose should be considered for children aged 19–23 months).
§ Persons who travel to or in areas where Neisseria meningitidis is hyperendemic or epidemic are at increased risk of exposure, particularly if contact with the
local population will be prolonged. Vaccination is especially recommended to those visiting the “meningitis belt” of sub-Saharah Africa during the dry season
(December–June), and vaccination is required by the government of Saudi Arabia for all travelers to Mecca during the annual Hajj. Advisories for travelers
are available at http://www.cdc.gov/travel/outbreaks.htm, http://www.cdc.gov/travel, or by calling CDC’s Travelers’ Health Hotline at 877-FYI-TRIP (toll-free).
¶ Microbiologists who are routinely exposed to isolates of N. meningitidis should be vaccinated.
** The use of vaccination in outbreak settings has been described previously (Source: CDC. Control and prevention of meningococcal disease, and Control
and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee
on Immunization Practices [ACIP]. MMWR 1997;46 [No. RR-5]:13–21).
†† Includes persons who have terminal complement component deficiencies and persons with anatomic or functional asplenia.
§ Calculation of attack rates for organization-based outbreaks is most useful
for sizable organizations (e.g., certain universities). However, for the majority
of organization-based outbreaks with three cases of disease, the rate will be
>10 cases/100,000 population. Thus, occurrence of three cases in these
settings should prompt consideration of vaccination. In certain situations,
public health officials also might consider vaccination after only two primary
cases are identified.
¶ To calculate a primary attack rate, sum all confirmed cases; exclude secondary
cases, and count each set of co-primary cases as one case. A primary case is
one that occurs in the absence of previous known close contact with another
patient. A secondary case is one that occurs among close contacts of a primary
patient >24 hours after onset of illness in the primary patient. If two or
more cases occur among a group of close contacts with onset of illness
separated by <24 hours, these cases are considered to be co-primary.
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MCV4 is preferred if the population targeted for vaccination
includes age groups for which MCV4 is licensed. Detailed
recommendations on evaluation and management of suspected
outbreaks of meningococcal disease have been published pre-
viously (4).
Administration
For persons aged 11–55 years, MCV4 is administered
intramuscularly as a single 0.5-mL dose. MPSV4 is adminis-
tered subcutaneously as a single 0.5-mL dose to persons aged
>2 years. MCV4 and MPSV4 can be administered concomi-
tantly with other vaccines, but at a different anatomic site
(4,117). Protective levels of antibodies are usually achieved
within 7–10 days of vaccination (60,118).
Revaccination
Revaccination might be indicated for persons previously
vaccinated with MPSV4 who remain at increased risk for
infection (e.g., persons residing in areas in which disease is
epidemic), particularly children who were first vaccinated at
age <4 years. Such children should be considered for revacci-
nation after 2–3 years if they remain at increased risk.
Although the need for revaccination among adults and older
children after receiving MPSV4 has not been determined,
antibody levels decline rapidly after 2–3 years, and, if indica-
tions still exist for vaccination, revaccination might be con-
sidered after 5** years (4). Repeated vaccination with serogroup
A and C polysaccharide vaccine might induce
immunologic hyporesponsiveness (56–59), although clinical
implications of such hyporesponsiveness are not known.
Hyporesponsiveness to serogroup C polysaccharide can be
overcome by vaccination with serogroup C conjugate vaccine
(119,120). MCV4 is recommended for revaccination of per-
sons aged 11–55 years; however, use of MSPV4 is acceptable.
ACIP expects that MCV4 will provide longer protection
than MPSV4; however, studies are needed to confirm this
assumption (87). More data will likely become available within
the next 5 years to guide recommendations on revaccination
for persons who were previously vaccinated with MCV4.
Precautions and Contraindications
Recommended vaccinations can be administered to persons
with minor acute illness (e.g., diarrhea or mild upper-
respiratory tract infection with or without fever) (117). Vac-
cination should be deferred for persons with moderate or severe
acute illness until the person’s condition improves. Vaccina-
tion with MCV4 or MPSV4 is contraindicated among
persons known to have a severe allergic reaction to any com-
ponent of the vaccine, including dipththeria toxoid (for
MCV4), or to dry natural rubber latex. Any adverse effect
suspected to be associated with MCV4 or MPSV4 vaccine
should be reported to the Vaccine Adverse Event Reporting
System (VAERS). More information about VAERS is avail-
able at 800-822-7967 (toll-free) or from http://www.vaers.org.
Because both MCV4 and MPSV4 are inactivated vaccines,
they may be administered to persons who are immunosup-
pressed as a result of disease or medications; however, response
to the vaccine might be less than optimal (117).
Studies of vaccination with MPSV4 during pregnancy have
not documented adverse effects among either pregnant women
or newborns (121–123). On the basis of these data, preg-
nancy should not preclude vaccination with MPSV4, if indi-
cated. MCV4 is safe and immunogenic among nonpregnant
persons aged 11–55 years, but no data are available on the
safety of MCV4 during pregnancy. Women of childbearing
age who become aware that they were pregnant at the time of
MCV4 vaccination should contact their health-care provider




MCV4 has been licensed on the basis of data regarding safety
and short-term immunogenicity. Postmarketing studies are
planned (98), including a study to evaluate the duration of
the antibody response among participants who had received a
single dose of MCV4 vaccine or MPSV4 vaccine 5 and 10
years earlier and a study to evaluate safety and immunogenic-
ity when MCV4 is given concomitantly with tetanus and
reduced diphtheria and acellular pertussis vaccine adsorbed
(Tdap). However, immunogenicity data alone are insufficient
to predict vaccine effectiveness and herd immunity effect,
which depends largely on the ability of vaccine to alter trans-
mission patterns. Additional studies are needed to evaluate
vaccine effectiveness, vaccine impact on nasopharyngeal
carriage of meningococci, and indirect effects of vaccine on
disease rates among unvaccinated populations.
Meningococcal conjugate vaccines might be considered for
licensing in the United States among persons in other age
groups, including infants and children aged <10 years (98).
These vaccines are undergoing clinical trials and are likely to
have better immunogenicity among infants and young chil-
dren than MPSV4 (124–126), which is the only vaccine avail-
able for these age groups in the United States. Information on
vaccine effectiveness, duration of protection, and herd
** Certain sources recommend revaccination after 3 years (4).
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immunity obtained from MCV4 evaluation studies will be
valuable in guiding prevention policies and formulating rec-
ommendations for vaccination of persons in other age groups.
Because serogroup B capsular polysaccharide is poorly
immunogenic in humans, vaccine development for serogroup
B meningococci have focused on common proteins, includ-
ing the outer membrane proteins (OMP) of specific epidemic
strains. Efficacy of OMP vaccines has been demonstrated
among older children and adults but not among infants and
young children, in whom rates of disease are highest
(127–130). In addition, the variability in OMP strains caus-
ing endemic disease will likely limit their usefulness in the
United States (131,132).
Because of the potential limitations of these vaccines, other
new approaches to serogroup B vaccines are being pursued,
including the conjugation of a modified serogroup B
polysaccharide (after substitution of the N-acetyl group with
an N-propionyl group) to a recombinant serogroup B menin-
gococcal porin protein. Although this vaccine is immunogenic
in mice and nonhuman primates, concern exists that the vac-
cine might not be safe (132). In addition, with the recent
sequencing of the serogroup B meningococcal genome, new
genes encoding putative membrane proteins have been iden-
tified, indicating potential new targets for serogroup B vac-
cines (133–135). The availability of new meningococcal
conjugate vaccines and the development of new vaccine strat-
egies should lead to substantial improvements in global
control and prevention of meningococcal disease.
Although the signs and symptoms of meningococcal dis-
ease are frequently nonspecific, increasing awareness for men-
ingococcal disease can result in earlier medical care-seeking
behavior and improved clinical outcomes. In addition, edu-
cating adolescents and their parents about the benefits of
receiving MCV4 is key to preventing a substantial number of
cases of meningococcal disease. Finally, educating policy mak-
ers and the general public about the benefits of receiving
MCV4 vaccine might improve vaccination coverage rates and
substantially decrease the burden of meningococcal disease in
the United States.
Antimicrobial Chemoprophylaxis
In the United States, the primary means for prevention of
sporadic meningococcal disease is antimicrobial chemopro-
phylaxis of close contacts of a patient with invasive meningo-
coccal disease (Table 7). Close contacts include 1) household
members (136,137), 2) child-care center contacts (136,138),
and 3) anyone directly exposed to the patient’s oral secretions
(e.g., through kissing, mouth-to-mouth resuscitation, endot-
racheal intubation, or endotracheal tube management). For
travelers, antimicrobial chemoprophylaxis should be consid-
ered for any passenger who had direct contact with respira-
tory secretions from an index-patient or for anyone seated
directly next to an index-patient on a prolonged flight (i.e.,
one lasting >8 hours). Guidelines for chemoprophylaxis of
travelers have been published previously (139). The attack rate
for household contacts exposed to patients who have sporadic
meningococcal disease was estimated to be four cases/1,000
persons exposed, which is 500–800 times greater than the rate
for the total population (137). In the United Kingdom, the
attack rate among health-care workers exposed to patients with
meningococcal disease was determined to be 25 times higher
than among the general population (140).
Because the rate of secondary disease for close contacts is
highest immediately after onset of disease in the index patient,
antimicrobial chemoprophylaxis should be administered as
soon as possible (ideally <24 hours after identification of the
index patient). Conversely, chemoprophylaxis administered
>14 days after onset of illness in the index patient is probably
of limited or no value. Oropharyngeal or nasopharyngeal cul-
tures are not helpful in determining the need for chemopro-
phylaxis and might unnecessarily delay institution of this
preventive measure.
TABLE 7. Schedule for administering chemoprophylaxis against meningococcal disease
Duration and route
Drug Age group Dosage of administration*
Rifampin† Children aged <1 mo 5 mg/kg body weight every 12 hrs 2 days
Children aged >1 mo 10 mg/kg body weight every 12 hrs 2 days
Adults 600 mg every 12 hrs 2 days
Ciprofloxacin§ Adults 500 mg Single dose
Ceftriaxone Children aged <15 yrs 125 mg Single IM¶ dose
Ceftriaxone Adults 250 mg Single IM dose
* Oral administration unless indicated otherwise.
†Not recommended for pregnant women because it is teratogenic in laboratory animals. Because the reliability of oral contraceptives might be affected by
rifampin therapy, consideration should be given to using alternative contraceptive measures while rifampin is being administered.
§Not usually recommended for persons aged <18 years or for pregnant and lactating women because it causes cartilage damage in immature laboratory
animals. Can be used for chemoprophylaxis of children when no acceptable alternative therapy is available. Recent literature review identified no reports of
irreversible cartilage toxicity or age-associated adverse events among children and adolescents (Source: Burstein GR, Berman SM, Blumer JL, Moran JS.
Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does the benefit outweigh the risk? Clin Infect Dis 2002;35:S191–9).
¶ Intramuscular.
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Rifampin, ciprofloxacin, and ceftriaxone are 90%–95%
effective in reducing nasopharyngeal carriage of N. meningitdis
and are all acceptable antimicrobial agents for chemoprophy-
laxis (141–144). Systemic antimicrobial therapy of meningo-
coccal disease with agents other than ceftriaxone or other
third-generation cephalosporins might not reliably eradicate
nasopharyngeal carriage of N. meningitdis. If other agents have
been used for treatment, the index patient should receive
chemoprophylactic antibiotics for eradication of nasopharyn-
geal carriage before being discharged from the hospital (145).
One recent study has reported that a single 500-mg oral
dose of azithromycin was effective in eradicating nasopharyn-
geal carriage of N. meningitdis (146). Azithromycin, in addi-
tion to being safe and easy to administer, is also available in a
suspension form and is approved for use among children.
Further evaluation is warranted of both the effectiveness of
azithromycin in eradicating carriage of N. meningitdis and
potential for development of microbial resistance to this drug
if it is widely used for chemoprophylaxis.
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5. Sign and date the response form or a photocopy of the form and send no
later than May 27, 2008, to
Fax: 770-488-8555  Mail: MMWR CE Credit
Division of Scientific Communications
Coordinating Center for Health Information
and Service, MS K-95
Centers for Disease Control and Prevention
1600 Clifton Rd, N.E.
Atlanta, GA 30333
6. Your Certificate of Completion will be mailed to you within 30 days.
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1. MCV4 and MPSV4 are not expected to be effective in preventing







2. Which three serogroups of N. meningitidis are responsible for the
majority cases of invasive meningococcal disease occurring in the
United States?
A. A, B, and C.
B. B, C, and Y.
C. C, Y, and W-135.
D. A, B, and Y.
E. A, C, and W-135.
3. Which group of U.S. college students is at highest risk for
meningococcal disease?
A. College students living in dormitories.
B. College freshmen.
C. Nonfreshmen.
D. College freshmen living in dormitories.
E. Nonfreshmen living in dormitories.
4. Which of the following antibiotics is not recommended for












6. Which of the following populations is not considered at increased risk
for meningococcal disease?
A. Military recruits.
B. Travelers to areas where an epidemic of meningococcal disease is
occurring.
C. Middle school students.
D. College students living in dormitories.
Goal and Objectives
This report provides recommendations on use of the newly licensed tetravalent meningococcal polysaccharide-protein conjugate vaccine (MCV4). The
recommendations were developed by CDC’s Advisory Committee on Immunization Practices (ACIP). The goal of this report is to provide recommendations for
clinicians, public health officials, and other persons concerned with controlling and preventing meningococcal disease in the United States on the use of MCV4 and
to update previous ACIP recommendations on prevention and control of meningococcal disease, including recommendations on use of the tetravalent
meningococcal polysaccharide vaccine (MPSV4). Upon completion of this educational activity, the reader should be able to 1) describe the epidemiology of
meningococcal disease in the United States; 2) describe the differences between polysaccharide and polysaccharide-protein conjugate meningococcal vaccines;
3) identify the populations for which MCV4 and MPSV4 are recommended; 4) describe the principles of evaluation and management of suspected outbreaks of
meningococcal disease; and 5) identify indications with appropriate drug schedules for antimicrobial chemoprophylaxis of meningococcal disease.
To receive continuing education credit, please answer all of the following questions.
E. Persons who have terminal complement component deficiency.
7. Which vaccine is recommended for young adolescents aged 11–12




C. Both MCV4 and MPSV4.
D. MCV4 is preferred, but MPSV4 is also acceptable.
E. MPSV4 is preferred, but MCV4 is also acceptable.
8. Which vaccine is recommended for vaccination of patients aged 60
years with anatomic asplenia?
A. MCV4.
B. MPSV4.
C. Both MCV4 and MPSV4.
D. MCV4 is preferred, but MPSV4 is also acceptable.
E. Neither MCV4 nor MPSV4 is recommended.
9. What are the expected characteristics of MCV4 and other
polysaccharide-protein conjugate vaccines?
A. Stimulate a T-cell–dependent immune system response.
B. Induce immunologic memory.
C. Confer protection in young children aged <2 years.
D. Reduce carriage of meningococcal serogroups included in the vaccine.
E. All of the above.
10. Who of the following is not considered a close contact of the patient
with meningococcal disease (and thus does not require
chemoprophylaxis)?
A. Mother of the patient living in the same house.
B. Co-worker who works in the office across the hall from the patient.
C. Person whom the patient was kissing frequently.
D. Child aged 2 years attending the same child care center as the patient.
E. Doctor who conducted endotracheal intubation when the patient was
hospitalized.






12. I plan to use these recommendations as the basis for . . . (Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.

















































































































































































































































































































































































































































































































































































































































































































































































































































































13. Each month, approximately how many vaccinations for meningococcal







14. How much time did you spend reading this report and completing the
exam?
A. <2.0 hours.
B. >2.0 hours but <3.0 hours.
C. >3.0 hours but <4.0.
D. >4.0 hours.
15. After reading this report, I am confident I can describe the
epidemiology of meningococcal disease in the United States.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident I can describe the differences




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can identify the populations
for which MCV4 and MPSV4 are recommended.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. After reading this report, I am confident I can describe the principles




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. After reading this report, I am confident I can identify indications with




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–10.
1. B; 2. B; 3. D; 4. B; 5. D; 6. C; 7. A; 8. B; 9. E; 10. B.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
23. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
24. The content of this activity was appropriate for my educational needs.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. The availability of continuing education credit influenced my
decision to read this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
26. How did you learn about this continuing education activity?
A. Internet.
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